Physician profile
Alia Brown
NPI 1679613871
$32,344.35
in general payments reported to CMS, 2019-2025
37 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,711 · 2020: $795 · 2021: $1,595 · 2022: $12K · 2023: $3,187 · 2024: $11K · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,580 · Consulting Fee: $6,600 · Travel and Lodging: $1,010 · Education: $159 · Grant: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,579.88 |
| Consulting Fee | $6,600.00 |
| Travel and Lodging | $1,010.23 |
| Education | $158.99 |
| Grant | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $8,668.78 | 2019-2024 | Tremfya |
| Abbvie INC. | $5,999.93 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $4,560.26 | 2019-2025 | |
| Leo Pharma INC. | $2,534.27 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Incyte Corporation | $2,448.96 | 2022-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $1,151.81 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,051.49 | 2019-2025 | |
| Lilly USA, LLC | $839.42 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $791.78 | 2019-2025 | Aklief, Epsolay, Oracea |
| Pfizer INC. | $723.27 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $572.02 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $422.25 | 2022-2025 | Sotyktu |
| Ucb, INC. | $404.56 | 2019-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $295.53 | 2022-2024 | Vtama |
| Merz North America, INC. | $258.93 | 2019-2023 | Xeomin |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $245.36 | 2019-2024 | |
| Amgen INC. | $243.94 | 2019-2023 | Otezla |
| Almirall LLC | $125.93 | 2019-2022 | |
| Celgene Corporation | $115.95 | 2019 | |
| Lumenis, INC | $110.53 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $103.53 | 2019-2024 | Jublia, Duobrii, Targretin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.98 | 2022-2025 | Spevigo, Cyltezo |
| Verrica Pharmaceuticals INC. | $87.32 | 2023-2024 | Ycanth |
| Allergan, INC. | $80.99 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $80.17 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $72.37 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $60.70 | 2020-2025 | |
| Biofrontera INC. | $43.49 | 2019 | |
| Strata Skin Sciences, INC. | $39.04 | 2019-2022 | |
| Botanix Sb INC | $32.75 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $24.22 | 2019 | |
| Dermira, INC. | $22.34 | 2019 | |
| Genentech USA, INC. | $19.61 | 2019 | |
| Organon LLC | $16.87 | 2025 | Vtama |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alia Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.